Breakthrough HepaRegeniX secures €15M in Series C funding
TLDR: HepaRegeniX, a German company, raised €15M in Series C funding for their regenerative therapy for liver diseases. The funding was led by Vesalius Biocapital IV with participation from existing investors. HepaRegeniX,